hVIVO Regulatory News (HVO)

hVIVO plc

("hVIVO", the "Company" or the "Group")

Director/PDMR Shareholding

& Total Voting Rights

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, was notified on 6 March 2025 that 6,440,119 options were exercised by Yamin Khan under the terms of the Company's Long Term Incentive Plan ("LTIP") at £0.001 per ordinary share.

Of the 6,440,119 options exercised, Mr Khan has sold 3,062,246 ordinary shares of £0.001 each in the Company ("Ordinary Shares") at 17p per Ordinary Share to meet the exercise cost and tax liabilities. Following this transaction, Mr Khan's holding in the Company is as detailed below:

Application will be made for 6,440,119 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to become effective on 13 March 2025. Following Admission, the Company will have 686,811,996 Ordinary Shares in issue. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. The total number of voting rights in the Company immediately following Admission will therefore be 686,811,996.

For further information please contact:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

​

Notes to Editors

hVIVO plc (Ticker: HVO) is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them: